Ozempic & Zepbound for PCOS: What the Evidence Shows

Neither Ozempic nor Zepbound is FDA-approved for PCOS, but both are widely prescribed for it, and the evidence is real if still thin. The best-controlled PCOS trial of a GLP-1 used liraglutide, an older daily drug, and found 5.7% weight loss in 32 weeks against 1.4% on placebo¹⁰. Studies of semaglutide (the drug in Ozempic and Wegovy) in women with PCOS report about 6 to 11 kg lost over four to six months, with periods returning in many of them¹¹¹³. The first tirzepatide (Zepbound, Mounjaro) data in PCOS arrived in 2026 and look at least as strong¹⁴¹⁵. Every study agrees on one thing: ovulation often comes back, so plan contraception before you start.

Why do GLP-1 medicines make sense for PCOS?

Polycystic ovary syndrome is, at its core, a metabolic condition as much as a reproductive one. Insulin resistance is a central driver for most women with PCOS, feeding higher androgen levels, irregular cycles and stubborn weight gain³. On the gold-standard clamp test, insulin resistance was present in 75% of lean women with PCOS and 95% of women with PCOS and overweight⁷. GLP-1 receptor agonists act on exactly this machinery: they slow gastric emptying, blunt appetite and improve the body's response to insulin, which is why they have become such a focus for women whose PCOS weight will not shift with diet and exercise alone⁴.

The 2023 international PCOS guideline, the one most US clinicians now follow, was the first to say anti-obesity medicines could be considered alongside lifestyle care for adults with PCOS and higher weight. It names liraglutide and semaglutide, and attaches three conditions: effective contraception when pregnancy is possible, slow dose increases to limit stomach side effects, and a warning that weight is likely to return if the medicine stops⁵.

The condition is also getting a new name. In 2026 a global consensus published in The Lancet renamed it polyendocrine metabolic ovarian syndrome, or PMOS, partly because the old name hides the metabolic side of the condition⁶. Most clinics, insurers and lab reports still say PCOS during the transition, so this guide does too. A few of the newest studies below use PMOS; it is the same diagnosis.

What do the PCOS trials actually show?

Here is every study in women with PCOS that this guide relies on, from strongest design to weakest:

Sources: liraglutide¹⁰, semaglutide with metformin¹³, tirzepatide with metformin¹⁴, low-dose semaglutide¹¹, semaglutide in 96 women¹², tirzepatide program records¹⁵.

Read the table with its limits in mind. Only the liraglutide trial was blinded against a placebo. The two metformin-combination trials came from the same hospital in Chongqing, China, and compared the GLP-1 plus metformin against metformin alone, so they show what adding the injection does, not what it does on its own. The semaglutide studies by Carmina and Longo had no comparison group. And in the UK tirzepatide records, PCOS was self-reported and only 40 women with PCOS had reached the 10-month mark, though their weight loss was no different from women without PCOS.

Pooled reviews say the same thing more cautiously. The review written for the 2023 guideline found only 11 trials of anti-obesity medicines in PCOS and called the data very limited⁸. A 2026 meta-analysis of 11 randomized trials found GLP-1 medicines lowered BMI by about 1.4 points more than comparison treatments, rated that low certainty, and found the evidence too thin to judge effects on glucose, insulin, excess hair or cycle regularity⁹. A May 2026 review concluded that liraglutide had the most PCOS-specific evidence, semaglutide's was sparse, and tirzepatide had none yet¹⁶. The two tirzepatide studies in the table were published after it.

How much weight can you expect?

The size of the effect comes mostly from the big obesity trials, which were not PCOS-specific but enrolled many women and are the best evidence for the medications themselves. In the STEP 1 trial, once-weekly semaglutide produced a mean body-weight reduction of roughly 15% over 68 weeks¹. Tirzepatide, a dual GIP/GLP-1 agonist, went further in SURMOUNT-1, with mean reductions around 20% at the highest dose². Because insulin resistance is so central to PCOS, many women and their clinicians are specifically interested in tirzepatide's metabolic effect, which is one reason we weight access to both molecules heavily in our Luna Fit Score.

The PCOS studies used lower doses and shorter courses than those trials, which is part of why their numbers look smaller. In the Carmina studies, women with overweight or milder obesity did best, and women with more severe obesity were less likely to respond¹¹¹².

For the full picture beyond medication (diet, activity, metformin and inositol), see our plan for losing weight with PCOS.

Ozempic or Zepbound for PCOS: which is better?

No trial has compared them head-to-head in PCOS. In the obesity trials, tirzepatide produced larger average weight loss¹², and its second hormone pathway draws interest given the insulin resistance behind PCOS. The dual GIP/GLP-1 agonist is the one women with insulin-resistant PCOS most often ask for by name, and our semaglutide versus tirzepatide comparison sets out what the head-to-head trial in obesity actually showed.

Two practical differences matter more for many women than the last few percent of weight:

• Evidence in PCOS. Semaglutide has more PCOS studies behind it, and the 2023 guideline names it. Tirzepatide's PCOS data are newer and smaller.
• The pill. Tirzepatide can make oral birth control less reliable. Its label advises switching to a non-oral method, or adding a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase¹⁷.

Either can be the right choice. It depends on your history, how you tolerate the first doses, cost and coverage, and your clinician's judgment.

Do GLP-1s help periods, ovulation and androgens?

Often, yes, though the evidence is weaker than it is for weight. In the liraglutide trial, the free androgen index (a measure of active testosterone) fell on the drug and rose slightly on placebo¹⁰. In the semaglutide studies, cycles normalized in 80% of women who lost at least 5% of their weight¹¹, and ovulation returned in about half of the women who had not been ovulating¹². In the combination trials, more women recovered regular cycles and more became pregnant once the GLP-1 stopped¹³¹⁴.

That is good news if you want a pregnancy later and a surprise if you do not. GLP-1 medicines are not appropriate during pregnancy or while trying to conceive, and improving insulin sensitivity can restore ovulation in women with PCOS, which can make pregnancy more likely than expected³. Read how long to stop each GLP-1 before trying to conceive before you start, and our guide on GLP-1s, birth control and fertility for which methods hold up. If you are actively pursuing pregnancy through IVF, that fertility-restoration effect raises its own timing questions our guide to GLP-1 before IVF and fertility treatment covers directly.

Can you take metformin with Ozempic or Zepbound for PCOS?

Yes, and many clinicians do. The 2023 guideline treats metformin and GLP-1 medicines as options alongside lifestyle care⁵, and both combination trials in the table added a weekly GLP-1 to twice-daily metformin¹³¹⁴. Combining them can add stomach side effects, so the doses should be managed by a clinician. Metformin is cheap and usually covered, which is why many women start there and add a GLP-1 if weight does not move.

Will insurance cover Ozempic for PCOS?

Usually not for PCOS itself, because no GLP-1 medicine is FDA-approved for PCOS. Ozempic is approved for type 2 diabetes, and Wegovy and Zepbound for chronic weight management, so coverage is judged on weight and weight-related conditions, not the PCOS diagnosis. Our PCOS weight-loss guide explains what prior-authorization forms ask for, and our guide to compounded vs brand-name GLP-1s covers the lower-cost route many women take when a plan says no.

When you want a PCOS-focused practice

A PCOS consultation and a medication subscription can cover different needs. Our PCOS Sisters review examines specialist visits, membership and the questions its published billing terms leave open. Before paying, ask which clinician can treat you in your state, which labs and prescriptions are included, and who manages concerns beyond weight. A PCOS label alone does not establish that every service or medication is part of the quoted fee.

What to ask a provider

The right provider for PCOS does more than mail a vial. Ask whether a licensed clinician reviews your history and runs or interprets labs; whether both semaglutide and tirzepatide are available so you are not locked into one molecule; and how titration and side effects are supported over the first months. These are the questions that separate a women's-metabolic program from a prescription service, and they are the factors our scoring looks at for every program, including our featured partner, CoreAge Rx. For a program built around PCOS rather than weight alone, see our review of Allara Health, which runs hormone labs first and prescribes brand-name GLP-1s through your own pharmacy when they fit. If you would rather see the whole field lined up on that one question than read about providers one at a time, we score every program we track on its PCOS and hormonal suitability score.

If you want an in-person team as well, start with which specialists treat PCOS and how to find one.

The cautions that matter for women

Stomach side effects are the most common reason women stop. In the liraglutide trial, 58% of women on the drug reported them, mostly mild to moderate¹⁰. Raising the dose slowly helps, and the guideline expects weight to return if the medicine is stopped, so treat this as a long-term plan rather than a short course⁵. GLP-1 medicines can also affect absorption of oral medications, which is why the birth-control point above matters.

None of this is a reason to avoid treatment; it is a reason to have it managed by a clinician who understands your hormones and goals. See the rest of our women's-health evidence library for the questions this one does not cover. PCOS also shares real biology with two conditions this site covers on their own: insulin resistance raises baseline gallstone risk alongside the estrogen effect already at play, covered in our gallstones guide, and a published case report has described a woman using a GLP-1 for co-occurring PCOS and idiopathic intracranial hypertension, a female-predominant headache condition our migraine and IIH guide explains.

A guideline-supported treatment is not automatically an insured benefit. Our PCOS insurance guide explains how the prescribed product, treatment indication and plan rules affect coverage.

We earn a commission when you start treatment through some links on this site, at no extra cost to you. CoreAge Rx is a featured partner, and providers we work with may appear first. Educational content, not medical advice. Talk to a licensed clinician before starting any treatment.